drugset
drugset / Trial / NCT05858684

Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients

NCT05858684 ↗

Phase 0 Recruiting 18 enrolled RenJi Hospital Gracell Biotechnologies (Shanghai) Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

This is an early exploratory phase, single arm, non-randomized, open label, treatment study trial to determine the maximum tolerated dose of GC012F injection (CD19-BCMA CAR-T cells) in patients with refractory systemic lupus erythematosus.

Timeline

Start
2023-05-11
Primary completion
2028-08-10
Completion
2029-06-10

Drugs

EvaluationDrugModalityDoseRoute
Subject GC012F Cell therapy 50000 cells/kg Intravenous
Subject GC012F Cell therapy 100000 cells/kg Intravenous
Subject GC012F Cell therapy 200000 cells/kg Intravenous
Subject GC012F Cell therapy 300000 cells/kg Intravenous

Indications

No indication recorded.